SMT201400196B - 6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato - Google Patents

6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato

Info

Publication number
SMT201400196B
SMT201400196B SM201400196T SM201400196T SMT201400196B SM T201400196 B SMT201400196 B SM T201400196B SM 201400196 T SM201400196 T SM 201400196T SM 201400196 T SM201400196 T SM 201400196T SM T201400196 B SMT201400196 B SM T201400196B
Authority
SM
San Marino
Prior art keywords
methylbutyl
purine
piperidinyl
maleate
dihydro
Prior art date
Application number
SM201400196T
Other languages
English (en)
Italian (it)
Inventor
Robert Hermann Gibbon
Amanda Lucas
Stephen Andrew Hermitage
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SMT201400196B publication Critical patent/SMT201400196B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
SM201400196T 2010-02-10 2014-12-30 6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato SMT201400196B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30301010P 2010-02-10 2010-02-10
PCT/EP2011/051830 WO2011098452A1 (en) 2010-02-10 2011-02-08 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate

Publications (1)

Publication Number Publication Date
SMT201400196B true SMT201400196B (it) 2015-01-15

Family

ID=43836817

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400196T SMT201400196B (it) 2010-02-10 2014-12-30 6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato

Country Status (23)

Country Link
US (1) US8703754B2 (enExample)
EP (1) EP2534149B1 (enExample)
JP (1) JP5922587B2 (enExample)
KR (1) KR101773541B1 (enExample)
CN (1) CN102753553B (enExample)
AU (1) AU2011214468B2 (enExample)
BR (1) BR112012018904A2 (enExample)
CA (1) CA2786973C (enExample)
DK (1) DK2534149T3 (enExample)
EA (1) EA021048B1 (enExample)
ES (1) ES2525826T3 (enExample)
HR (1) HRP20141258T1 (enExample)
IL (1) IL220845A (enExample)
ME (1) ME01926B (enExample)
MX (1) MX2012009316A (enExample)
PL (1) PL2534149T3 (enExample)
PT (1) PT2534149E (enExample)
RS (1) RS53745B1 (enExample)
SG (1) SG182471A1 (enExample)
SI (1) SI2534149T1 (enExample)
SM (1) SMT201400196B (enExample)
WO (1) WO2011098452A1 (enExample)
ZA (1) ZA201205995B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
AU2012289042A1 (en) 2011-07-22 2014-03-13 Glaxosmithkline Llc Composition
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
JP6246121B2 (ja) * 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
MX359671B (es) 2012-08-24 2018-10-05 Glaxosmithkline Llc Star Compuestos de pirazolopiridina.
WO2014081643A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
PL2922549T3 (pl) 2012-11-20 2017-11-30 Glaxosmithkline Llc Nowe związki
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
JP7109188B2 (ja) * 2014-08-29 2022-07-29 コリウム， インコーポレイテッド 活性剤の送達のための微細構造アレイ
MX2017006302A (es) * 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
US12130267B2 (en) * 2018-11-28 2024-10-29 Shimadzu Corporation Analyzing method for azo compound
CN118026811A (zh) * 2022-11-14 2024-05-14 中国科学院大连化学物理研究所 二氢吡喃与醋酸为原料联产1,5-戊二醇和乙醇的方法
CN118063285A (zh) * 2022-11-14 2024-05-24 中国科学院大连化学物理研究所 煤与生物质耦合利用生产醇的方法
TW202541845A (zh) 2023-12-29 2025-11-01 南韓商賽特瑞恩股份有限公司 穩定醫藥製劑

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1065213A3 (en) 1999-07-02 2003-11-05 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
IL157940A0 (en) 2001-03-19 2004-03-28 Ono Pharmaceutical Co Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003085375A2 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
BR0315417A (pt) 2002-10-24 2005-08-16 Glaxo Group Ltd Derivados 1-acil-pirrolidina para o tratamento de infecções virais
AU2003300911A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
US7271172B2 (en) 2002-12-13 2007-09-18 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as CCR5 antagonists
JP2006512339A (ja) 2002-12-13 2006-04-13 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのインダン化合物
AU2003296993A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
ES2311755T3 (es) 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
RU2005118407A (ru) 2002-12-13 2006-03-10 СмитКлайн Бичем Корпорейшн (US) Производные пиперидина в качестве антагонистов ccr5
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
UY28758A1 (es) 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
WO2005105761A1 (en) 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2361845T3 (es) 2004-08-18 2011-06-22 Pfizer, Inc. Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos.
US20060045885A1 (en) 2004-08-27 2006-03-02 Kedl Ross M Method of eliciting an immune response against HIV
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
EP1939198A4 (en) * 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
EP2125792B1 (en) 2007-02-19 2010-12-01 GlaxoSmithKline LLC Purine derivatives as immunomodulators
SI2132209T1 (sl) * 2007-03-19 2014-05-30 Astrazeneca Ab Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7)
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US8777708B2 (en) 2008-06-27 2014-07-15 Microsoft Corporation Targeting control in a simulated environment
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань

Also Published As

Publication number Publication date
PL2534149T3 (pl) 2015-03-31
EP2534149A1 (en) 2012-12-19
DK2534149T3 (da) 2015-01-05
EP2534149B1 (en) 2014-10-15
EA021048B1 (ru) 2015-03-31
PT2534149E (pt) 2014-12-23
CN102753553A (zh) 2012-10-24
KR20120135408A (ko) 2012-12-13
KR101773541B1 (ko) 2017-08-31
CN102753553B (zh) 2016-03-30
JP5922587B2 (ja) 2016-05-24
SG182471A1 (en) 2012-08-30
HRP20141258T1 (hr) 2015-02-27
ES2525826T3 (es) 2014-12-30
CA2786973C (en) 2018-04-10
MX2012009316A (es) 2012-09-12
RS53745B1 (sr) 2015-06-30
ME01926B (me) 2015-05-20
JP2013519645A (ja) 2013-05-30
CA2786973A1 (en) 2011-08-18
IL220845A (en) 2016-08-31
BR112012018904A2 (pt) 2020-09-01
WO2011098452A1 (en) 2011-08-18
AU2011214468B2 (en) 2015-05-28
EA201290631A1 (ru) 2013-03-29
US20120308609A1 (en) 2012-12-06
US8703754B2 (en) 2014-04-22
SI2534149T1 (sl) 2015-02-27
AU2011214468A1 (en) 2012-08-09
ZA201205995B (en) 2014-01-29

Similar Documents

Publication Publication Date Title
DK2534149T3 (da) 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
IL266285A (en) Methods for the production of tian compounds [d - 3,2] pyrimidine
EP2624698A4 (en) Furo [3,2-D] PYRIMIDINE COMPOUNDS
AP2939A (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors
PT2776442E (pt) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas de receptor 2 de canabinóides
BRPI1014459A2 (pt) derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"
ZA201201295B (en) Substituted xanthine derivatives
ZA201209029B (en) Novel pyrimidine derivatives
EP2786257A4 (en) RING PROTOCOL FOR LOW LATENCY INTERCONNECTION SWITCH
IL232304A0 (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
IL210173A0 (en) Substituted alkyl pyrimidin-4-one derivatives
ZA201404176B (en) 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives
IL231783A0 (en) History of ethinyl as allosteric modulators of 5mglur
IL232717A0 (en) 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives
EP2507841A4 (en) TEXTURED SUPERSTRATES FOR PHOTOVOLTAICS
DK2421869T3 (da) Rifamycinderivat
IL219603A0 (en) Imidazopyridine derivatives
EP2516420B8 (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
IL219635A0 (en) Heterocyclic sulfonamide derivatives
HUE037649T2 (hu) (Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-il vegyületek, mint duális aktivitású H1 inverz agonisták/5-HT2A antagonisták
AU2011355362B2 (en) 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives
HK1187783A (en) Furo[3,2-d]pyrimidine compounds
HK1171015A (en) Heterocyclic sulfonamide derivatives
HK1196363A (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
HK1188994A (en) Novel heterocyclic derivatives